Attached files
| file | filename |
|---|---|
| EX-99.1 - EXHIBIT 99.1 - SURMODICS INC | a52211450ex99_1.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
|
April 29, 2020
|
||
|
Date of report (Date of earliest event reported)
|
|
Surmodics, Inc.
|
||
|
(Exact Name of Registrant as Specified in its Charter)
|
|
Minnesota
|
0-23837
|
41-1356149
|
||
|
(State of Incorporation)
|
(Commission File Number)
|
(I.R.S. Employer
Identification No.)
|
|
9924 West 74th Street
Eden Prairie, Minnesota
|
55344
|
|
|
(Address of Principal Executive Offices)
|
(Zip Code)
|
|
(952) 500-7000
|
||
|
(Registrant’s Telephone Number, Including Area Code)
|
Check the appropriate box below if the Form 8‑K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction
A.2):
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a‑12 under the Exchange Act (17 CFR 240.14a‑12)
☐ Pre‑commencement communications pursuant to Rule 14d‑2(b) under the Exchange Act (17 CFR 240.14d‑2(b))
☐ Pre‑commencement communications pursuant to Rule 13e‑4(c) under the Exchange Act (17 CFR 240.13e‑4(c))
Securities registered pursuant to Section 12(b) of the Act:
|
Title of Each Class
|
Trading Symbol(s)
|
Name of Each Exchange on Which Registered
|
|
Common Stock, $0.05 par value
|
SRDX
|
Nasdaq Global Select Market
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the
Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
|
Emerging growth company
|
☐
|
|
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided
pursuant to Section 13(a) of the Exchange Act.
|
☐
|
|
Item 2.02
|
|
Results of Operations and Financial Condition.
|
On April 29, 2020, Surmodics, Inc. (the “Company”) issued a press release (the “Press Release”) announcing the results for the quarter ended March 31, 2020. A copy
of the full text of the Press Release is furnished as Exhibit 99.1 to this report.
The information contained in this Item 2.02, including Exhibit 99.1, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as
amended, nor shall they be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such a filing.
|
Item 9.01
|
|
Financial Statements and Exhibits.
|
|
|
|
|
|
(d)
|
|
Exhibits.
|
|
|
|
Exhibit
|
||
|
|
|
Number
|
Description | |
|
|
|
99.1
|
Press Release dated April 29, 2020. |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly
authorized.
| SURMODICS, INC. | ||
|
Date: April 29, 2020
|
/s/ Timothy J. Arens | |
| Timothy J. Arens | ||
| Vice President of Finance and Chief Financial Officer | ||
EXHIBIT INDEX
|
Exhibit
Number
|
Description
|
|